Safety of Breast Conserving Treatment in Locally Advanced Breast Cancer Receiving Neoadjuvant Treatment

N/ATerminatedNCT02017496

Oslo University Hospital18 enrolled

Overview

The study explores the safety of breast conserving treatment (BCT)(defined as complete removal of tumor deposits) after neoadjuvant treatment for locally advanced breast cancer.

The standard breast surgical procedure of locally advanced breast cancer in Norway is mastectomy. There is increasing interest in performing breast conserving treatment (BCT) in locally advanced cases after chemotherapy or hormonal treatment - if there is a partial or complete clinical remission. To increase the evidence for the safety (no residual tumor) of such a procedure directly compared to mastectomy without compromising the safety of the treatment, a breast preserving procedure followed by an immediate mastectomy can be performed within a study. It would then be possible to study the margins after the breast preserving procedure as well as the tumor status in the rest of the breast. Patients included in the study will receive neoadjuvant treatment followed by evaluation of the tumor reduction by magnetic resonance imaging (MRI) and selection of BCT candidates. Candidates will be prepared for BCT, and during the surgical procedure, BCT will be performed (as one surgical specimen) followed by immediate removal of the rest of the breast tissue (mastectomy). The BCT specimen and mastectomy specimen will be analysed for residual tumor cells. The tumor removal completeness of the BCT procedure can be evaluated, with comparison to the clinical and primary tumor characteristics, including analysis of the tumor biopsies and imaging before and during the neoadjuvant treatment, for selection of candidates for BCT in the future.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * Patients with locally advanced breast cancer (cT3-4c, N0-3) with tumors \> 5 cm, as determined by MRI, where the present guidelines include them for neoadjuvant systemic therapy * Written informed consent (informed consent document to be approved by the Independent Ethics Committee) prior to study-related procedures and examinations. * Female age \> 18 years * Able to comply with the protocol * Histologically confirmed adenocarcinoma of the breast * American Society of Anesthesiologist's physical status category 1 or 2 before surgery. Category 1 and 2 includes healthy patients and patients with only mild systemic disease, whereas category 3 includes patients with more serious systemic diseases (but still operable). Exclusion criteria: * Inflammatory breast cancer or diffuse locoregional involvement of the skin * Stage IV - metastatic disease * Locoregional relapse of earlier breast cancer * Inability (irrespective of reason) to receive the recommended neoadjuvant treatment, - as decided by the treating physician. * American Society of Anesthesiologist's physical status category 4-5

Locations (1)

Oslo University Hospital

Oslo, Norway

Outcomes

Primary Outcomes

1 The presence of viable tumor cells at the margins and in the mastectomy specimen after conducted breast preserving resection followed by mastectomy in the same procedure

The surgical specimens will be analysed after surgery, and the results of these analyses will be the basis for the final end point measurements.

Time frame: 24 weeks after start of neoadjuvant treatment (at surgery)

Secondary Outcomes

Tumor molecular marker characteristics related to complete resection by BCT

Tumor molecular marker characteristics, MRI, mammography (Mx) and ultrasound (US) results and clinical parameters in patients with residual tumor cells in the mastectomy specimen compared to those with no tumor cells

Time frame: 24 weeks after start of neoadjuvant treatment (at surgery)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.